Sunday, April 24, 2022 11:23:43 PM
Well said Bourbon, that is where he can easily 'show us the money'. Yet here we sit with the stock at $10. SMH
High dose improved all patients, and importantly without any adverse effects.
The data from the Ph-2 trial is a hands down winner, a foregone conclusion for FDA approval.
People need to pepper Dr. M with questions at the ASM about the tortoise rate of follow up trials.
Especially PDD/PD which is still not in a Phase -3 since the highly successful results were PRed in June of last year.
Where is the PDD/PD paper that was to be published, if you have the trial results in hand, how long does it take?
